Gliclazide 21187-98-4

99% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Gliclazide
CAS No.	21187-98-4
Molecular Formula	C15H21N3O3S
Molecular Weight	323.4105
Quality Standard	99% up by HPLC, Medical Grade
Appearance	White powder

COA of Gliclazide

Item	Specification	Test Result
Characteristics	White or almost white powder	White powder
Solubility	Practically insoluble in water: freely soluble in methylene chloride; Sparingly soluble in acetone(96%); slightly soluble in alcohol (96%)	Conforms
M.P	162-166°C	164.0-164.5° C
Identification	Conform to the spectrum of the CRS Gliclazide	Conforms
Heavy metals	≤10ppm	<10ppm
Impurity B	≤2ppm	0.3ppm
Related substances	Impurity F ≤0.10%	<0.10%
	Other single impurity ≤0.10%	<0.10%
	Total of other impurities ≤0.2%	<0.13%
Loss on drying	≤0.25%	0.10%
Sulphated ash	≤0.1%	0.01%
Residual solvents	Ethyl acetate ≤0.5%	Below LOQ
Residual solvents	Toluene ≤0.089%	Below LOQ
Assay (on dried basis)	99.0%-101.0%	99.5%
Conclusion	The Results Conforms With Enterprise Standards

Usage

Function of Gliclazide

Gliclazide is a second-generation sulfonylurea hypoglycemic drug, which is a secretion promoter. Its hypoglycemic mechanism is to selectively act on the β cells of the pancreatic islets to promote the secretion of insulin and increase the secretion of insulin after eating, so that the liver Glycogen production and output are inhibited, which is helpful for the prevention and treatment of diabetic microvascular disease. Gliclazide has a long and stable action time, and is generally used in elderly patients. Gliclazide is generally absorbed quickly after oral administration, reaching a peak in 3-4 hours, and 80% is excreted from the kidneys. If the kidney function is not good, attention should be paid. Less common side effects are gastrointestinal reactions, such as nausea and vomiting, and the incidence of hypoglycemia is less than that of other sulfonylureas. Gliclazide can be used alone or simultaneously with other hypoglycemic drugs. Its hypoglycemic level is practical and reliable, and it can be combined with biguanides, insulin sensitizers, DPP-4 inhibitors and insulin, and different combinations can be made according to different conditions of patients.

*Products under the patent are only for R&D use